# Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease

> **NCT01203631** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 78 (actual)

## Conditions studied

- Inflammation
- Crohn's Disease

## Interventions

- **DRUG:** NNC 0142-0000-0002
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01203631
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2016-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01203631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01203631, "Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT01203631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*